Success Metrics

Clinical Success Rate
100.0%

Based on 2 completed trials

Completion Rate
100%(2/2)
Active Trials
5(71%)
Results Posted
0%(0 trials)

Phase Distribution

Ph not_applicable
1
14%
Ph phase_2
3
43%
Ph phase_3
1
14%

Phase Distribution

0

Early Stage

3

Mid Stage

1

Late Stage

Phase Distribution5 total trials
Phase 2Efficacy & side effects
3(60.0%)
Phase 3Large-scale testing
1(20.0%)
N/ANon-phased studies
1(20.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

2 of 2 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

5

trials recruiting

Total Trials

7

all time

Status Distribution
Active(5)
Completed(2)

Detailed Status

Recruiting5
Completed2

Development Timeline

Analytics

Development Status

Total Trials
7
Active
5
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 23 (60.0%)
Phase 31 (20.0%)
N/A1 (20.0%)

Trials by Status

completed229%
recruiting571%

Recent Activity

5 active trials
Showing 5 of 7
recruitingphase_2

Intratumoral INT230-6 Followed by Neoadjuvant Immuno-chemotherapy in Patients With Early TNBC. INVINCIBLE-4-SAKK

NCT06358573
completednot_applicable

Neoadjuvant Immunochemotherapy vs Chemoradiotherapy in ESCC

NCT07236320
recruitingphase_2

Surufatinib in Combination With Neoadjuvant Chemo-immunotherapy and Concurrent Chemoradiotherapy for Patients With Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma

NCT07086469
recruitingphase_2

Neoadjuvant Immunochemotherapy for Locally Advanced Cervical Cancer: a Prospective, Single-arm, Phase II Clinical Trial

NCT07003620
completed

Neoadjuvant Immunochemotherapy for Lung Cancer

NCT06023797
View all 7 trials

Clinical Trials (7)

Showing 7 of 7 trials
NCT06358573Phase 2

Intratumoral INT230-6 Followed by Neoadjuvant Immuno-chemotherapy in Patients With Early TNBC. INVINCIBLE-4-SAKK

Recruiting
NCT07236320Not Applicable

Neoadjuvant Immunochemotherapy vs Chemoradiotherapy in ESCC

Completed
NCT07086469Phase 2

Surufatinib in Combination With Neoadjuvant Chemo-immunotherapy and Concurrent Chemoradiotherapy for Patients With Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma

Recruiting
NCT07003620Phase 2

Neoadjuvant Immunochemotherapy for Locally Advanced Cervical Cancer: a Prospective, Single-arm, Phase II Clinical Trial

Recruiting
NCT06023797

Neoadjuvant Immunochemotherapy for Lung Cancer

Completed
NCT05974007

Neoadjuvant Treatment Real-world Clinical Outcomes in NSCLC

Recruiting
NCT04280822Phase 3

Neo-adjuvant Immunochemotheray Versus Neo-adjuvant Chemotherapy for Resectable Esophageal Carcinoma

Recruiting

All 7 trials loaded

Drug Details

Intervention Type
OTHER
Total Trials
7